The estimated Net Worth of Chrystal Jensen is at least 1.77 百万$ dollars as of 15 August 2024. Chrystal Jensen owns over 16,667 units of Cerus stock worth over 972,202$ and over the last 12 years Chrystal sold CERS stock worth over 796,051$.
Sign up
Chrystal Jensen CERS stock SEC Form 4 insiders trading
Chrystal has made over 14 trades of the Cerus stock since 2016, according to the Form 4 filled with the SEC. Most recently Chrystal sold 16,667 units of CERS stock worth 34,501$ on 15 August 2024.
The largest trade Chrystal's ever made was exercising 211,327 units of Cerus stock on 22 December 2020 worth over 923,499$. On average, Chrystal trades about 23,854 units every 106 days since 2013. As of 15 August 2024 Chrystal still owns at least 474,245 units of Cerus stock.
You can see the complete history of Chrystal Jensen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Chrystal Jensen's mailing address?
Chrystal's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE SUITE 600, CONCORD, CA, 94520.
Insiders trading at Cerus
Over the last 21 years, insiders at Cerus have traded over 5,083,598$ worth of Cerus stock and bought 1,382,745 units worth 4,903,526$ . The most active insiders traders include William Mariner Greenman、Laurence M Corash、Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of 90,805$. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth 178,539$.
What does Cerus do?
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
What does Cerus's logo look like?
Complete history of Chrystal Jensen stock trades at Cerus
Cerus executives and stock owners
Cerus executives and other stock owners filed with the SEC include:
-
William Greenman,
President, Chief Executive Officer, Director -
Vivek Jayaraman,
Chief Operating Officer, Chief Commercial Officer -
Laurence Corash,
Chief Scientific Officer -
Richard Benjamin,
Chief Medical Officer -
Kevin Green,
Chief Financial Officer, Vice President - Finance -
Carol Moore,
Senior Vice President - Regulatory Affairs, Quality and Clinical -
Chrystal Menard,
Chief Legal Officer and General Counsel -
Jami Nachtsheim,
Independent Director -
Daniel Swisher,
Independent Chairman of the Board -
Timothy Anderson,
Independent Director -
Frank Witney,
Independent Director -
Gail Schulze,
Independent Director -
Eric Bjerkholt,
Independent Director -
Timothy Moore,
Independent Director -
Tim Lee,
Investor Relations Director -
William J Dawson,
Chief Financial Officer -
Caspar Jan Hogeboom,
Managing Director Cerus Europe -
Bruce C Cozadd,
Director -
David N Cook,
Vice President, R & D -
Chrystal Jensen,
Chief Legal Officer -
Stephen T Isaacs,
Chief Executive Officer -
Gregory W Schafer,
Chief Financial Officer -
International Inc & Subsidi...,
10% owner -
C Raymond Jr Larkin,
Director -
Bj Cassin,
Director -
Howard G Ervin,
Vice President, Legal Affairs -
Claes Glassell,
Executive Officer and Director -
William R Rohn,
Director -
Dean A. Gregory,
-
Ann Lucena,
Director -
Hua Shan,
Director